Related Experiment Video
Updated: Jun 19, 2026

Assays for the Specific Growth Rate and Cell-binding Ability of Rotavirus
Published on: January 28, 2019
Rotavirus gastroenteritis in uzbekistan: implications for vaccine policy in central Asia
Elmira T Flem1, Erkin Musabaev, Rivojiddin Juraev
1Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway. elmira.flem@fhi.no
Insights
Rotavirus infections significantly impact children under 5 in Uzbekistan, causing many hospitalizations and deaths. Introducing rotavirus vaccines could be cost-effective for the national immunization program.
Area of Science:
- Pediatric Infectious Diseases
- Vaccinology
- Public Health Surveillance
Background:
- Rotavirus is a leading cause of severe gastroenteritis in young children globally.
- Uzbekistan, with the largest birth cohort in Central Asia, is a key region for evaluating rotavirus vaccine impact.
- The country's eligibility for international vaccine introduction funds necessitates understanding the disease burden.
Purpose of the Study:
- To assess the burden of rotavirus disease in Uzbekistan among children under 5 years.
- To determine the potential cost-effectiveness of rotavirus vaccine introduction in the national immunization program.
Main Methods:
- Surveillance of rotavirus in stool samples from children under 5 with gastroenteritis (2005-2006).
- Estimation of national rotavirus-associated mortality and hospitalization rates.
- Genotyping of rotavirus strains.
Main Results:
- Rotavirus was detected in 30% of 3537 children studied; 80% of infections occurred in children under 2.
- The G1P[8] genotype was the most common strain identified in 2005.
- Annual estimates suggest 1174-1857 deaths and 6394-6558 hospitalizations due to rotavirus in children under 5.
Conclusions:
- Rotavirus accounts for a substantial proportion of gastroenteritis hospitalizations and deaths in young children in Uzbekistan.
- Introducing rotavirus vaccines at subsidized prices may be a cost-effective public health intervention.
Background:
To determine the value of rotavirus vaccines in Central Asia, we conducted surveillance of rotavirus in Uzbekistan, the country with the largest birth cohort in the region. Uzbekistan is eligible for international funds to introduce new vaccines.
Methods:
We screened stool samples for rotavirus that were collected from children aged <5 years with gastroenteritis in 2 hospitals during 2005-2006. Using surveillance information and other data, we estimated national numbers of rotavirus-associated events per year.
Results:
Of 3537 enrolled children, 1046 (30%) had rotavirus detected in stool specimens. Children aged <2 years accounted for 841 (80%) of all rotavirus infections. The G1P[8] genotype was identified in 27 (52%) of 52 typed samples collected in 2005. Rotavirus is estimated to cause 1174-1857 deaths and 6394-6558 hospitalizations among children aged <5 years annually. The cumulative risk of hospitalization for rotavirus by age 5 years is 1 in 94-96 children, and the risk of rotavirus-related death is 1 in 330-524 children.
Conclusions:
One-third of all hospitalizations for gastroenteritis and almost 5% of all deaths among children aged <5 years in Uzbekistan may be attributable to rotavirus. Introduction of rotavirus vaccines into the national immunization program at the current subsidized prices could be cost-effective.
Related Concept Videos
Poliomyelitis
Bacterial Gastroenteritis
Respiratory Syncytial Virus Disease
Smallpox
Yellow Fever
Vaccinations
